| value |
{"aggregator_url":"https://news.google {"aggregator_url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNb09QOEFYLXhkNVY5eEpLQndCM2lUWHJFOVkwNTByaUxGS1pjZ1RtWGoyU0gwZXZxQTAzVTgxdHFiMXJKeU51UUR5LXBSRmJHM19EVko4SEVxd3RkSl9WLWdySlFobDJRRjExQlZsN2dTeXBhd3ozbS0welltMmdrbVdZb2RkY1FudG8za0ZuVk8yd0Y0?oc=5","as_of":"2026-04-09T16:35:58.987693+00:00","canonical_url":"https://www.gstatic.com/_/mss/boq-dots/_/ss/k=boq-dots.DotsSplashUi_desktop_ms.OYgPNdDf9Nc.L.X.O/am=GAIFAAAADpgFDCgAAQ/d=1/ed=1/rs=ALs0n2OYSmDAUDetpsORI83j3dpsv55GJQ/m=syndicationarticleview,_b,_tp","enrichment":{"aggregator_url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNb09QOEFYLXhkNVY5eEpLQndCM2lUWHJFOVkwNTByaUxGS1pjZ1RtWGoyU0gwZXZxQTAzVTgxdHFiMXJKeU51UUR5LXBSRmJHM19EVko4SEVxd3RkSl9WLWdySlFobDJRRjExQlZsN2dTeXBhd3ozbS0welltMmdrbVdZb2RkY1FudG8za0ZuVk8yd0Y0?oc=5","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_bd1daadc26c2aa45","canonical_host":"gstatic.com","canonical_is_aggregator":true,"canonical_url":"https://www.gstatic.com/_/mss/boq-dots/_/ss/k=boq-dots.DotsSplashUi_desktop_ms.OYgPNdDf9Nc.L.X.O/am=GAIFAAAADpgFDCgAAQ/d=1/ed=1/rs=ALs0n2OYSmDAUDetpsORI83j3dpsv55GJQ/m=syndicationarticleview,_b,_tp","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-10T02:27:25.711050+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"","final_url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNb09QOEFYLXhkNVY5eEpLQndCM2lUWHJFOVkwNTByaUxGS1pjZ1RtWGoyU0gwZXZxQTAzVTgxdHFiMXJKeU51UUR5LXBSRmJHM19EVko4SEVxd3RkSl9WLWdySlFobDJRRjExQlZsN2dTeXBhd3ozbS0welltMmdrbVdZb2RkY1FudG8za0ZuVk8yd0Y0?oc=5&hl=en-US&gl=US&ceid=US:en","html_truncated":true,"paywall_likely":false,"publisher_domain":"gstatic.com","publisher_resolution":"canonical_aggregator_unresolved","requested_url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNb09QOEFYLXhkNVY5eEpLQndCM2lUWHJFOVkwNTByaUxGS1pjZ1RtWGoyU0gwZXZxQTAzVTgxdHFiMXJKeU51UUR5LXBSRmJHM19EVko4SEVxd3RkSl9WLWdySlFobDJRRjExQlZsN2dTeXBhd3ozbS0welltMmdrbVdZb2RkY1FudG8za0ZuVk8yd0Y0?oc=5","source_event_id":"evt_4f8c4f20e1de","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"839ae62dca9fe56b","kind":"ipo_calendar","published_at":"2026-04-09T15:55:17+00:00","publisher_domain":"gstatic.com","signal_understanding":{"analysis_basis":"headline_and_summary","claim_confidence":0.74,"dates_mentioned":[],"entities":[{"asset_class":"equity (planned IPO; symbol not provided)","name":"Avalyn","relevance":"high","symbol":"","type":"company"}],"event_type":"listing","information_gaps":["No IPO date/timeline is provided.","No IPO size, pricing, underwriters, exchange, or ticker symbol is provided.","The specific lung disease/indication is not named in the provided text.","No clinical stage, trial results, or pipeline details are provided.","No financial metrics (revenue, cash, burn) are provided.","The provided article text appears to contain only page styling/HTML fragments, not the article body; therefore details beyond the headline cannot be extracted."],"key_facts":["BioPharma Dive headline states: \"Chasing a tough-to-treat lung disease, Avalyn plans an IPO.\""],"numeric_claims":[],"primary_claim":"Avalyn plans an IPO to pursue a tough-to-treat lung disease.","relevance_score":0.62,"sentiment":"neutral","source_quality":"high","summary":"The article reports that Avalyn is planning an IPO to pursue a tough-to-treat lung disease. No additional IPO timing, terms, or disease specifics are present in the provided text.","topics":["IPO","biopharma","lung disease","tough-to-treat disease"]},"source":"BioPharma Dive","source_domain":"gstatic.com","summary":"Chasing a tough-to-treat lung disease, Avalyn plans an IPO BioPharma Dive","tickers":[],"title":"Chasing a tough-to-treat lung disease, Avalyn plans an IPO - BioPharma Dive","url":"https://www.gstatic.com/_/mss/boq-dots/_/ss/k=boq-dots.DotsSplashUi_desktop_ms.OYgPNdDf9Nc.L.X.O/am=GAIFAAAADpgFDCgAAQ/d=1/ed=1/rs=ALs0n2OYSmDAUDetpsORI83j3dpsv55GJQ/m=syndicationarticleview,_b,_tp"}... |